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AminopurinolAfrican trypanosomes, like all obligate parasitic protozoa, cannot synthesize purines de novo and import
purines from their hosts to build nucleic acids. The purine salvage pathways of Trypanosoma brucei being
redundant, none of the involved enzymes is likely to be essential. Nevertheless they can be of pharma-
cological interest due to their role in activation of purine nucleobase or nucleoside analogues, which only
become toxic when converted to nucleotides. Aminopurine antimetabolites, in particular, are potent try-
panocides and even adenine itself is toxic to trypanosomes at elevated concentrations. Here we report on
the T. brucei adenine phosphoribosyltransferases TbAPRT1 and TbAPRT2, encoded by the two genes
Tb927.7.1780 and Tb927.7.1790, located in tandem on chromosome seven. The duplication is syntenic
in all available Trypanosoma genomes but not in Leishmania. While TbAPRT1 is cytosolic, TbAPRT2 pos-
sesses a glycosomal targeting signal and co-localizes with the glycosomal marker aldolase. Interestingly,
the distribution of glycosomal targeting signals among trypanosomatid adenine phosphoribosyltransfe-
rases is not consistent with their phylogeny, indicating that the acquisition of adenine salvage to the gly-
cosome happened after the radiation of Trypanosoma. Double null mutant T. brucei Dtbaprt1,2 exhibited
no growth phenotype but no longer incorporated exogenous adenine into the nucleotide pool. This, how-
ever, did not reduce their sensitivity to adenine. The Dtbaprt1,2 trypanosomes were resistant to the ade-
nine isomer aminopurinol, indicating that it is activated by phosphoribosyl transfer. Aminopurinol was
about 1000-fold more toxic to bloodstream-form T. brucei than the corresponding hypoxanthine isomer
allopurinol. Aminopurinol uptake was not dependent on the aminopurine permease P2 that has been
implicated in drug resistance.
 2013 The Authors. Published by Elsevier Ltd. All rights reserved.1. Introduction
A common feature of most pathogens – viruses, bacteria, proto-
zoa or tumor cells – is their fast proliferation and, consequently,
high demand for nucleotides to replicate their genomes. Thus
purine and pyrimidine analogues are widely used as chemothera-peutic agents. These are usually administered as nucleobase or
nucleoside prodrugs that, once taken up by a target cell, need to
be phosphorylated to the corresponding nucleotide in order to
exert cytotoxic activity by inhibiting DNA or RNA polymerases.
Knowledge on the molecular nature of a pathogen’s nucleotide
salvage pathways will therefore promote the rational design of
nucleobase or nucleoside antimetabolites that, ideally, are speciﬁ-
cally phosphorylated by the target organism but not by human
cells.
Like all obligate parasitic protozoa, Trypanosoma brucei ssp. do
not synthesize purines de novo (Fish et al., 1982a,b), having lost
the genes of the purine anabolic pathway, presumably in adapta-
tion to parasitism. The trypanosomes therefore depend on salvage
of purines from their hosts: the tsetse ﬂies (Glossina spp.) and
mammals. Trypanosoma brucei rhodesiense and T. b. gambiense
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mans, also known as human African trypanosomiasis (HAT). The
parasites proliferate extracellularly in the blood and eventually
cross the blood–brain barrier, with fatal consequences for the pa-
tient. Purines are taken up from the blood by several transporters
of overlapping substrate speciﬁcities (de Koning et al., 2005). The
aminopurines adenine and adenosine are thought to be the favorite
purine source of bloodstream-form T. brucei since of all physiolog-
ical purines, these are taken up the fastest (Fish et al., 1982a).
Adenosine is imported via P1- and P2-type transporters, adenine
is taken up via P2, H2 and H3 (Carter and Fairlamb, 1993; de
Koning and Jarvis, 1997). The pharmacological importance of try-
panosomal purine permeases was underscored by the ﬁndings that
P2 also transports trypanocidal drugs like melarsoprol, diminazene
and pentamidine (Carter and Fairlamb, 1993; Carter et al., 1995),
and that loss of the gene encoding P2, TbAT1, reduces the sensitiv-
ity to these drugs (Mäser et al., 1999; Matovu et al., 2003).
Homozygous deletion of TbAT1 in T. brucei also resulted in
resistance to adenosine analogs such as cordycepin (30-deoxyaden-
osine) or tubercidin (7-deazaadenosine; Geiser et al., 2005;
Lüscher et al., 2007).
Adenine at high (e.g. millimolar) concentrations is toxic to try-
panosomes (Taliaferro and D’Alesandro, 1971; Geiser et al., 2005).
Adenine toxicity is a phenomenon also known from Escherichia coli,
where it is exacerbated by genetic disruption of hypoxanthine and
guanine phosphoribosyltransferases (E.C. 2.4.2.8) and counteracted
by addition of guanosine (Levine and Taylor, 1982). This clearly
indicates that an excess of adenine may be cytotoxic to E. coli be-
cause it disturbs the cellular purine balance by depleting the guan-
ine pool and increasing the ratio of [AMP] to [GMP]. However, it is
unknown whether adenine has the same effect on T. brucei. The
purine salvage machinery of bloodstream-form T. brucei is able to
interconvert all the physiological purine nucleobases, nucleosides,
and nucleotides (Fish et al., 1982a). Interestingly, some of the en-
zymes involved localize to the glycosomes, which are membrane-
bound organelles of kinetoplastid parasites that are devoted
mainly to glycolysis but are also involved in other metabolic path-
ways including purine salvage and pyrimidine biosynthesis
(Opperdoes and Michels, 1993).
Glycosomal proteins carry targeting signals that are very similar
to the known peroxisomal targeting signals (PTS), suggesting a
common evolutionary origin of glycosomes and peroxisomes
(Michels et al., 2005). Two types of PTS are known: serine-lysine-
leucine (PTS1) or similar tripeptides at the C-terminus of
glycosomal proteins, or a less conserved nonapeptide (PTS2) at
the N-terminus of glycosomal proteins (Petriv et al., 2004).
Hypoxanthine-guanine phosphoribosyltransferases identiﬁed from
Leishmania spp., Trypanosoma cruzi and T. brucei all carried C-termi-
nal PTS1 signals, and in T. brucei and Leishmania were localized to
the glycosomes (Hassan et al., 1985; Shih et al., 1998a,b).
Leishmanial HGPRTases are of high pharmacological interest since
they accept allopurinol as a substrate (Hwang et al., 1996); human
HGPRT is also able to phosphoribosylate allopurinol although it is a
poor substrate (Krenitsky et al., 1969) but, unlike in hemoﬂagel-
lates the resulting allopurinol riboside is not converted to amino-
purinol riboside and consequently is not incorporated into
nucleic acids (Hitchings, 1975; Shapiro et al., 1991). Allopurinol
[4-hydroxypyrazolo(3,4-d)pyrimidine; HPP], used in humans pri-
marily against hyperuricemia (e.g. gout) but also against leishman-
ioses, is a close structural isomer of hypoxanthine that carries the
nitrogen at position 8 instead of 7 in the purine ring. Allopurinol is
very active against Leishmania spp. and T. cruzi (Berens et al., 1982;
Apt et al., 2003), but less so against T. brucei (Marr and Berens,
1983; Natto et al., 2005; de Koning, unpublished). The analogous
N8 isomer of adenine, aminopurinol (4-aminopyrazolopyrimidine;
APP) exhibits promising activity against T. brucei (Wallace et al.,2002; Natto et al., 2005). Here we identify and characterize the
two APRT genes from T. b. brucei with particular respect to the sub-
cellular localization of the gene products and their role in amino-
purinol susceptibility.2. Materials and methods
2.1. Cultivation of trypanosomes, transfection, drug sensitivity tests
Bloodstream-form T. b. brucei 221 (MITat 1.2) were cultivated in
HMI-9 medium (Hirumi and Hirumi, 1989) and 10% FCS at 37 C in
a humidiﬁed atmosphere at 5% CO2. Procyclic T. b. brucei 427 were
cultivated at 27 C in SDM-79 (Brun and Schönenberger, 1979)
supplemented with 5% fetal calf serum and 1 lg ml1 hemin. For
stable transfection, 108 procyclic or 2  107 bloodstream-form try-
panosomes were washed and resuspended in 450 ll of electropor-
ation buffer (120 mM KCl, 150 mM CaCl2, 4 mM MgCl2, 8.7 mM
K2HPO4, 1.3 mM KH2PO4, 25 mM HEPES, 2 mM EDTA), mixed with
10 lg linearized plasmid DNA, and electroporated at 1.5 kV; antibi-
otic selection started 24 h after transformation. Positive transfor-
mants were cloned by limiting dilution and veriﬁed by PCR as
well as Southern blots. Drug sensitivities were determined with
the AlamarBlue assay at inocula of 103 (bloodstream forms) or
5  104 (procyclics) and 72 h of incubation (Räz et al., 1997). The
read-out was ﬂuorescence, measured at wavelengths 530 nm for
excitation and 590 nm for emission (Spectromax Gemini). IC50 val-
ues were calculated by non-linear ﬁtting of the data to a sigmoidal
dose-response curve with variable slope (Prism, GraphPad Soft-
ware). All compounds were purchased from Sigma except 7-dea-
zaadenine (Berry&Associates). Isothermal microcalorimetry was
performed as described (Wenzler et al., 2012). Bloodstream-form
cells, 105 in 2 ml HMI-9 medium and 10% horse serum, were inoc-
ulated to calorimetry ampoules. Drugs were added to the desired
concentration and the ampoules were immediately sealed and
placed into the microcalorimeter (TAM III, TA Instruments, New
Castle DE, USA). Ampoules containing medium without trypano-
somes served as negative controls, ampoules containing trypano-
somes without drugs served as positive controls. All experiments
were carried out twice, each in triplicate.2.2. TbAPRT constructs and primers
The constructs for replacement by homologous recombination
of the TbAPRT1,2 locus with selectable markers were made by ligat-
ing 160 bp of the TbAPRT1 50-UTR, ampliﬁed by PCR from genomic
DNA with primers KO180for (50-ccggtaccgtcacttgtggaggttttgc-30)
and KO180rev (50-ccaagcttgcgcatcacttcaggatttt-30), and 160 bp of
the TbAPRT2 30-UTR, ampliﬁed with KO200for (50-ccggtaccgt-
cacttgtggaggttttgc-30) and KO200rev (50-gctctagacacagtcgtgacctgg-
taatg-30), to either side of hygromycin (ﬁrst round) or neomycin
(second round) resistance genes cloned into pBluescript II SK+.
Veriﬁcation of positive transformants by Southern blot was done
using as probes cloned PCR products speciﬁc to TbAPRT1, ampliﬁed
with primers Fw180 (50-aatcttcagcagcccatcac-30) and Rev180
(50-gcgttcctttgaggaaagtg-30), or TbAPRT2, ampliﬁed with Fw200
(50-atgccaattgtgctcacgta-30) and Rev200 (50-gccacatcacagacggtaag-
30). The same probes were used for Northern blots on total RNA
isolated with the hot phenol method (Roditi et al., 1989). The con-
structs for C-terminal in situ tagging were created by PCR using as
template plasmid pMOTag3H containing a triple hemagglutinin tag
(100 bp) plus neomycin resistance gene (800 bp) for TbAPRT1, and
pMOTag3xM4 containing a triple Myc tag (520 bp) plus hygromy-
cin resistance gene (1 kb) for TbAPRT2. Chimeric primers were
used which consisted of the last 80 nt of the target TbAPRT coding
region (forward) – respectively the ﬁrst 80 nt of the target TbAPRT
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template plasmid (Oberholzer et al., 2006). PCR products of the
expected size for directly electroporated into trypanosomes and
positive transformants were veriﬁed by PCR and sequencing for
in-frame insertion of the tag.
2.3. Immunoﬂuorescence
For immunoﬂuorescence, 2  106 bloodstream-form or 107 pro-
cyclic trypanosomes were washed with PBS supplemented with
10 g/l glucose, and spread onto Diagnostic Microscope Slides (Erie
Scientiﬁc) which had been coated for 30 min with polylysin
(100 lg/ml; Sigma). The cells were ﬁxed with 4% paraformalde-
hyde in phosphate-buffered saline (PBS), washed three times with
PBS (for procyclic forms supplemented with 0.1 M glycine), and
permeabilized with 0.1% tritonX-100 (bloodstream forms) or
0.05% Tween-20 (procyclics) in PBS. The cells were washed three
times with PBS and (procyclics only) incubated for 10 min in meth-
anol at 20 C followed by rehydration in PBS. After blocking with
2% BSA, the slides were incubated for 45 min in PBS plus 2% BSA
with the primary antibody: for TbAPRT1 monoclonal mouse anti-
HA diluted 1:300 (Roche), for TbAPRT2 monoclonal mouse
anti-myc at 1:100 (Santa Cruz), for aldolase monoclonal rabbit
anti-aldolase at 1:10,000 (kind gift of Paul Michels, Université
Catholique de Louvain, Brussels). After three washes, the slides
were incubated in the dark for 45 min with the secondary
antibody: goat anti-mouse Alexa Fluor 488 (Invitrogen) or goat
anti-rabbit 594 (Molecular Probes) at 1:1000. The slides were
washed three times and mounted in Vectashield containing
1.5 lg/ml DAPI (Vector laboratories, Inc.).
2.4. Cell fractionations
For Western blots, total cell lysates of 107 cells were run on 10%
SDS-polyacrylamide gels and transferred to nitrocellulose mem-
branes (Immobilon-P, Millipore) in 3 g/l Tris, 14.4 g/l glycine, 20%
methanol. After blocking in TBS (10 mM Tris–HCl pH 7.4,
150 mM NaCl) plus 5% milk powder, the blots were hybridized
for 1.5 h with primary antibody (1:1000 for anti-HA and anti-
Myc; 1:100,000 for anti-aldolase), washed three times in TBS
0.05% Tween-20, and incubated for 1.5 h with the secondary anti-
body (rabbit anti mouse-HRP; Dako). Signals were detected using
ECL-plus (Amersham Biosciences). For digitonin extraction of pro-
teins, 2.5  107 cells per assay were washed in SBG (22 mM glu-
cose, 150 mM NaCl, 20 mM NaHPO4 pH 7.8), resuspended in
125 ll SoTE (0.6 M sorbitol, 20 mM Tris–HCl pH 8.0, 2 mM EDTA),
and carefully mixed with an equal volume of digitonin at the indi-
cated concentration. After 5 min on ice, soluble (supernatant of
6800 g) and insoluble (pellet of 20,000 g) fractions were separated
by centrifugation.
2.5. Purine transport assays
Uptake of [3H]-hypoxanthine and [3H]-adenosine (both from GE
Healthcare) was performed essentially as described previously (de
Koning and Jarvis, 1997, 1999). Bloodstream trypanosomes T. b.
brucei 221 were cultivated in HMI-9 medium for the adenosine up-
take studies and isolated from adult female Wistar rats for the
hypoxanthine uptake experiments, separating parasites from blood
cells on DE52 anion exchange columns (Whatman) and washed
into standard assay buffer (AB) as described (de Koning and Jarvis,
1999). Radiolabel concentrations for assaying H2, H3 and P2 activ-
ity were 0.1 lM [3H]-hypoxanthine, 1 lM [3H]-hypoxanthine and
0.05 lM [3H]-adenosine, respectively, and incubation time with
radiolabel was 30 s. Assays were performed in AB (33 mM HEPES,
98 mM NaCl, 4.6 mM KCl, 0.55 mM CaCl2, 0.07 mM MgSO4,5.8 mM NaH2PO4, 0.3 mM MgCl2, 23 mM NaHCO3, 14 mM glucose,
pH 7.3) and incubations were terminated by the addition of 1 mM
unlabelled permeant in ice-cold AB followed by centrifugation
through oil (30 s, 12,000g). Radioactivity in the ensuing cell pellet
was determined by liquid scintillation counting. Data was analyzed
on GraphPad Prism 5.0 using non-linear regression after subtrac-
tion of non-speciﬁc radiolabel binding. When inhibition with
aminopurionol was between 50% and 100% of uptake, incomplete
inhibition curves were extrapolated to yield IC50 value based on
the assumption of full inhibition and a Hill slope of 1. To measure
incorporation of adenine into the nucleotide pool, procyclic trypan-
osomes were incubated at 107 cells ml1 in AB plus 1 lM [3H]-ade-
nine at 27 C for a maximum of 10 min, washed with ice-cold
buffer, and extracted in 0.1 M HCl by freeze-thawing. After centri-
fugation at 12,000 g, samples of the supernatant were spotted onto
silica thin-layer chromatography plates (Merck LuxPLate 60F254)
and run with a mixture of n-butanol, ethyl acetate, methanol and
ammonia of 7:4:3:4 (vol). Nucleotide and nucleobase standards
were run alongside the samples. Radiolabel was quantiﬁed by
scanning the air-dried plates in a radioisotope detector (Berthold
Technologies, Switzerland).3. Results and discussion
3.1. Trypanosoma brucei possesses two adenine
phosphoribosyltransferases
The T. b. brucei genome (Berriman et al., 2005) was annotated to
contain two putative APRT genes in tandem on chromosome VII:
Tb927.7.1780 and Tb927.7.1790. The two predicted proteins return
highly signiﬁcant expectancy of 1031 and 1018, respectively,
when run with HMMer (Eddy, 1998) against the phosphoribosyl-
transferase proﬁle PF00156 from Pfam (Finn et al., 2008). We
screened the predicted T. brucei proteome (version 4; 9192 pro-
teins) for further phosphoribosyltransferase domains using
HMMer with Pfam proﬁle PF00156. This search returned nine hits
with E-values below 1012. The predicted proteomes of T. cruzi and
Leishmania major were searched as well, and the mammalian host
Homo sapiens was included as a reference. All the hits with an
expectancy below 1010 were aligned with ClustalW (Thompson
et al., 1994). In the resulting phylogenetic tree (Supplementary
Figure S1), the two T. brucei proteins Tb927.7.1780 and
Tb927.7.1790 clustered with the known APRTases from L. major
and H. sapiens and were therefore named TbAPRT1 and TbAPRT2.
The APRT clade is proximate to the orotate phosphoribosyltransfe-
rases (OPRT; EC 2.4.2.10) and clearly distinct from the HGPRT
(2.4.2.8)/XPRT (2.4.2.22) clade (Figure S1).
The two predicted proteins TbAPRT1 and TbAPRT2 share only
24% identity at the level of amino acids, and a nucleotide dot plot
of the region encompassing the two genes does not reveal any sim-
ilarities at the level of genomic DNA (not shown). Thus if the tan-
dem location of TbAPRT1 and TbAPRT2 resulted from the
duplication of a primordial gene, it must have been an ancient
event. This presumed duplication is older than the radiation of Try-
panosoma spp. since the tandem APRT locus is syntenic in Trypan-
osoma congolense, Trypanosoma vivax and T. cruzi [tritrypdb.org].
In contrast, Leishmania spp. possess only one APRT gene per gen-
ome, indicating that the presumed APRT duplication in Trypano-
soma happened after the divergence from Leishmania (or that
APRT2 was lost from the common ancestor of the Leishmania
spp.; Fig. 1). The situation is different regarding HGPRT genes,
which form tandem duplications in Trypanosoma as well as in
Leishmania (Fig. 1). The two leishmanial genes encode for hypoxan-
thine-guanine and xanthine phosphoribosyltransferases, respec-
tively. Genetic disruption of either gene was viable in Leishmania
Fig. 1. Phylogenetic tree of trypanosomatid predicted APRT and HGPRT proteins
plus human APRT (UniProt P07741) and HGPRT (UniProt P00492) as outgroups.
Proteins with a C-terminal PTS1 signal as predicted by the PTS1 Predictor
(Neuberger et al., 2003) are labeled with an asterisk. Bootstrapping values for the
major branches are given as percent positives of 1000 rounds. The scale bar
indicated number of changes per site. For the Trypanosoma tandem genes, the one
upstream was labeled as number one. GeneDB accession numbers are
Tc00.1047053508207.74 (TcrAPRT1), Tc00.1047053508207.70 (TcrAPRT2),
TcIL3000.0.32550 (TcoAPRT1), TcIL3000.7.1260 (TcoAPRT2), TvY486_0701640
(TviAPRT1), TvY486_0701650 (TviAPRT2), LmjF26.0140 (LmaAPRT),
Tb927.10.1400 (TbrHGPRT1), Tb927.10.1390 (TbrHGPRT2), TcIL3000.10.1180
(TcoHGPRT1), TcIL3000.10.1170 (TcoHGPRT2), TvY486_1001390 (TviHGPRT1),
TvY486_1001370 (TviHGPRT2), Tc00.1047053506457.30 (TcrHGPRT1),
Tc00.1047053506457.40 (TcrHGPRT2), LmjF21.0845 (LmajHGPRT), LmjF21.0850
(LmajXPRT).
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tants were synthetic lethal (Boitz and Ullman, 2006a, 2010).
To experimentally test the predicted adenine phosphoribosyl-
transferase function, we generated homozygous T. b. brucei
tbaprt1,tbaprt2 double knock-out mutants (procyclic forms). A re-
gion of 2150 bp encompassing the two TbAPRT genes was replaced,
via homologous recombination, with selectable constructs contain-
ing hygromycin and neomycin resistance genes. Positive transfor-
mants were cloned by limiting dilution and correct integration of
the constructs into the TbAPRT1,2 locus was veriﬁed by Southern
blots (Supplementary Figure S2). The resulting Dtbaprt1,2 trypano-
somes grew as fast as their ‘wild-type’ parents (Fig. 2a) in standard
cultivation medium; the population doubling times were 14.2 h for
‘wild-type’ and 13.4 h for Dtbaprt1,2 trypanosomes. However,
when incubated with [3H]-adenine the Dtbaprt1,2 trypanosomes
did not incorporate radiolabel into the nucleotide pool to signiﬁ-
cant levels (Fig. 2b), demonstrating that Dtbaprt1,2 mutants lackFig. 2. Homozygous disruption of TbAPRTs in procyclic T. brucei. (a) Double null
mutant Dtbaprt1,2 trypanosomes (black diamonds) grew as fast as wild-type (white
circles) in SDM-79. The cultures were diluted regularly during the experiment and
the dilution factors accounted for in the virtual concentration given on the y-axis.
(b) In contrast to wild-type trypanosomes, the Dtbaprt1,2 mutants did not
incorporate [3H]adenine into the nucleotide pool as determined by thin layer
chromatography of cells lysed at the indicated time points. Error bars represent
standard deviation of three independent experiments.APRTase activity. The requirement of APRT to incorporate adenine
into the nucleotide pool is consistent with the absence of an ade-
nine deaminase activity in T. b. brucei, which is believed to be pres-
ent only in T. vivax (Ogbunude and Ikediobi, 1983) as well as in
Leishmania spp. (LaFon et al., 1982). Salvage of [3H]-hypoxanthine
was not impaired in Dtbaprt1,2 trypanosomes (not shown).
3.2. Subcellular localization of TbAPRT1 and TbAPRT2 in trypanosomes
The genes TbAPRT1 and TbAPRT2 are expressed in bloodstream-
form as well as in procyclic, tsetse ﬂy midgut-stage trypanosomes
as determined by Northern blot analysis (Fig. 3a), which is in
agreement with existing proteomics data (Vertommen et al.,
2008). Steady-state mRNA levels of TbAPRT2 appeared to be higher
in procyclic than in bloodstream-form trypanosomes (Fig. 3a).
While the predicted protein TbAPRT2 possesses a bona ﬁde glyco-
somal targeting signal (serine-arginine-leucine), TbAPRT1 does
not. To experimentally investigate their subcellular localization,
the TbAPRT1 and the TbAPRT2 gene products were tagged C-termi-
nally with haemagglutinin and c-myc, respectively, by homologous
recombination in situ (Oberholzer et al., 2006). Heterozygous
transformants carrying one tagged allele of either TbAPRT1 or
TbAPRT2 were selected by means of the incorporated neomycin,
respectively hygromycin, resistance markers and cloned by limit-
ing dilution. Differential lysis of cells was performed with digito-
nin, which at lower concentration (0.1 mg digitonin per mg
protein) only dissolves the plasma membrane whereas at higher
concentration (0.6 mg per mg protein) it also dissolves organellar
membranes. Differential lysis followed by Western blotting
(Fig. 3b) or direct immunoﬂuorescence of ﬁxed cells (Fig. 4) dem-
onstrated that TbAPRT1 localized to the cytosol while TbAPRT2
co-localized with the glycosomal marker aldolase. The result that
a C-terminal myc tag apparently did not prevent TbAPRT2 from
getting to the glycosome might be explained by the fact that APR-
Tase is a dimeric enzyme. We speculate that a dimer containing
one tagged subunit and one with a free C-terminal PTS1 could still
be targeted to the glycosome. Peroxisomal proteins are imported
folded and oligomeric (Leon et al., 2006). The presence of TbAPRT2
in the glycosomes implies that there ought to be an aminopurine
permease in the glycosomal membrane. Genes encoding permeas-
es for purine nucleobases, including adenine, have been identiﬁed
from T. brucei (Mäser et al., 1999; Burchmore et al., 2003; Henriques
et al., 2003; Ortiz et al., 2009). Several of these transporters were
localized to the plasma membrane (Henriques et al., 2003; Ortiz
et al., 2009) but no evidence exists for a glycosomal location.
Leishmania have only one APRTase and it is a cytosolic enzyme
(Zarella-Boitz et al., 2004). The South-American T. cruzi and the
African T. brucei each possess two APRTase paralogues. An interest-
ing difference between T. brucei and T. cruzi emerged when the
presence of predicted glycosomal targeting signals was overlaid
to the phylogeny of phosphoribosyl transferases (Fig. 1). While
TbAPRT2 carries a PTS1 and TbAPRT1 does not, the situation is re-
versed in T. cruzi where TcAPRT1 has a PTS1 and TcAPRT2 does not
(Fig. 1). The distribution of glycosomal targeting signals among try-
panosomatid phosphoribosyltransferases is generally not consis-
tent with their phylogeny (Figs. 1 and S1). An interesting case is
presented by the phosphoribosyl-pyrophosphate synthetases
(PRS; EC 2.7.6.1): T. brucei, T. cruzi and L. major each possess three
PRS paralogues, of which in every species a different one is pre-
dicted to be targeted to the glycosome (Figure S1). In summary,
this argues that the recruitment of adenine salvage enzymes to
the glycosome happened independently, after the radiation of try-
panosomatids. The physiological role of purine salvage enzymes in
the glycosomes is unclear, since replacement of glycosomal XPR-
Tase in L. donovani with a truncated, cytosolic form did not impair
purine salvage (Zarella-Boitz et al., 2004).
Fig. 3. Expression of TbAPRT1 and TbAPRT2 in T. brucei. (a) The genes are expressed in procyclic and in bloodstream-form trypanosomes as determined by Northern blot,
TbAPRT2 more strongly in the procyclics (a probe of the 18S rRNA was used as a loading control). (b) Western blots of the in situ-tagged gene products after digitonin lysis of
the cells. While TbAPRT1 was in the soluble fraction (S, supernatant) even at low digitonin concentration, TbAPRT2 and the glycosomal marker aldolase were in the insoluble
fraction (P, pellet) at low digitonin concentration.
Fig. 4. Immunoﬂuorescence microscopy of procyclic T. brucei: wildtype (left), HA-tagged TbAPRT1 cells (middle), and Myc-tagged TbAPRT2 cells (right). (A) DAPI staining, (B)
anti-TbAPRT stain (anti-HA for TbAPRT1 and wildtype, and anti-myc for TbAPRT2), (C) anti-aldolase stain, (D) overlay of B and C. TbAPRT2 but not TbAPRT1 appeared to
co-localize with aldolase.
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While adenosine antimetabolites such as cordycepin, tuberci-
din, or vidarabine are known as potent trypanocides (Bacchi
et al., 1992; Kaminsky et al., 1996; Bressi et al., 2001; Drew
et al., 2003; Geiser et al., 2005; Rodenko et al., 2007; Vodnala
et al., 2008), adenine antimetabolites have so far received little
attention (Wallace et al., 2002, 2004). Yet, adenine analogues are
attractive trypanocides for many reasons. As mentioned above, try-
panosomes lack adenine and adenosine deaminase (Ogbunude and
Ikediobi, 1983), making adenine analogues highly stable. Secondly,
T. brucei express at least three separate adenine transporters in
bloodstream forms: the aminopurine transporter P2 (de Koning
et al., 2005), and the broad speciﬁcity nucleobase transporters H2and H3 (de Koning and Jarvis, 1997). Uptake by multiple transport-
ers greatly reduces the chances of resistance through loss of trans-
porter function, as we previously demonstrated for allopurinol
(Natto et al., 2005) and pentamidine (de Koning, 2008). Moreover,
adenines have a higher rate of membrane diffusion than hypoxan-
thine analogues or nucleosides; in Toxoplasma gondii adenine sal-
vage was found to be non-saturable and consistent with simple
diffusion (De Koning et al., 2003), made possible by a favourable
octanol:water partition coefﬁcient XLogP3 (Cheng et al., 2007) of
just 0.1.
We determined the sensitivity of different T. brucei lines to ade-
nine and analogues with an in vitro test using the ﬂuorescent dye
AlamarBlue as an indicator of cell viability (Räz et al., 1997). As
observed previously (Taliaferro and D’Alesandro, 1971; Geiser
Fig. 6. Real-time isothermal microcalorimetry with bloodstream-form T. b. brucei
exposed to aminopurinol (green, 7.5 lM; blue, 15 lM; magenta, 25 lM; dark blue,
45 lM), pentamidine (red, 15 nM), or no drug at all (black). The curves are averages
of triplicates, except for the negative control without trypanosomes (grey). The
experiment was performed as described (Wenzler et al., 2012). (For interpretation
of the references to colour in this ﬁgure legend, the reader is referred to the web
version of this article.)
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value around 300 lM (Fig. 5); bloodstream-form and procyclic T.
brucei were equally sensitive. Adenine toxicity in E. coli is thought
to be linked to an imbalance between cellular GTP and ATP levels
(Levine and Taylor, 1982). In T. brucei, however, deletion of TbAPRT
did not alleviate adenine toxicity (Fig. 5). As the adenine was no
longer incorporated into the nucleotide pool (Fig. 2b) this means
that in trypanosomes adenine toxicity is not caused by an imbal-
ance between [ATP] and [GTP]. Furthermore, adenine toxicity in
E. coli could be counteracted by addition of excess guanosine
(Levine and Taylor, 1982), which is not the case in T. brucei (data
not shown). Our conclusion that adenine toxicity in trypanosomes
is not linked to increased adenine nucleotide levels is in agreement
with the fact that adenosine, which gets incorporated to the nucle-
otide pool by adenosine kinase (Lüscher et al., 2007), has no effect
on T. b. brucei growth rates up to millimolar concentrations. Thus,
the mechanism of adenine toxicity in trypanosomes remains
elusive.
In Leishmania, allopurinol is converted to allopurinol riboside
monophosphate by HGPRT, aminated to aminopurinol riboside
monophosphate in two steps by adenylosuccinate synthetase and
-lyase, and then phosphorylated to the triphosphate which gets
incorporated into RNA (Marr et al., 1978). Phosphoribosyl transfer
to allopurinol is very inefﬁcient in mammalian cells (Krenitsky
et al., 1969) with most being rapidly metabolized to oxipurinol
(Hitchings, 1975). The approximately 10% of allopurinol converted
to allopurinol riboside monophosphate is not accepted by human
adenylosuccinate synthetase whereas it can substitute for IMP as
a substrate for the corresponding enzyme of Leishmania (Spector
et al., 1984). Similarly, allopurinol riboside monophosphate is an
inhibitor of L. donovani GMP reductase with 100-fold weaker activ-
ity against the human enzyme (Spector et al., 1984).
While these observations explain the therapeutic window of
allopurinol for the treatment of leishmanioses and Chagas’ disease,
allopurinol was not potent against T. brucei (IC50 against blood-
stream forms of 170 lM; not shown). In contrast, aminopurinol
exhibited submicromolar activity against T. brucei bloodstream
forms with an IC50 value of 190 nM (Fig. 5). To determine whether
amimopurinol acts in a cytostatic or a cytotoxic way, bloodstream-
form trypanosomes were subjected to isothermal microcalorime-
try. This technique allows to non-invasively monitor cell prolifera-
tion in real time by measuring the produced heat ﬂow (Wenzler
et al., 2012). In contrast to the cytotoxic reference drug pentami-
dine, aminopurinol did not kill the trypanosomes but merely inhib-
ited their growth (Fig. 6).Fig. 5. Structure of adenine and aminopurinol and activity against bloodstream-
form (BSF) T. b. brucei, procyclic forms (PCF), and procyclic forms carrying a
homozygous deletion of the complete TbAPRT1 and TbAPRT2 locus (Daprt1,2).
Activity was determined in vitro with the Alamar blue assay Hirumi and Hirumi,
1989.3.4. Uptake of allopurinol and aminopurinol by T. brucei bloodstream
forms
An alternative explanation for the much greater efﬁcacy of ami-
nopurinol could lie in more efﬁcient uptake of this prodrug. We
previously reported allopurinol inhibition constants for the T. b.
brucei nucleobase transporters H2 and H3 (Ki values of 4.0 and
194 lM, respectively; (de Koning and Jarvis, 1997)). We report
here that these transporters in fact display lower afﬁnity for ami-
nopurinol (Fig. 7), with Ki values of 230 ± 35 and 105 ± 24 lM for
H2 and H3, respectively. In addition, we determined the Ki value
for the P2 aminopurine transporter at 75.3 ± 5.7 lM (n = 6; Fig. 7)
– lower than for allopurinol (Ki = 260 lM) (de Koning and Jarvis,
1999), but much higher than for adenine (Ki = 0.3 lM). Thus, N8
appears to be unfavourable for binding to P2. We tested whether
aminopurinol activity was dependent on P2 expression using a
Dtbat1 strain (Matovu et al., 2003), but found no resistance to ami-
nopurinol (Fig. 8) although we observed 18-fold resistance to
diminazene, consistent with previous reports (de Koning et al.,
2004). We thus conclude that the remarkable efﬁcacy of aminopur-
inol versus allopurinol against T. b. brucei is highly unlikely to be
related to more efﬁcient uptake. Instead, it is most likely attribut-
able to the much more efﬁcient conversion of the prodrug to the
active compound, aminopurinol riboside triphosphate. As allopuri-
nol is a substrate for TbHGPRT (Allen and Ullman, 1993) it must be
the adenylosuccinate synthetase/lyase step that is principally
responsible for the striking difference.
3.5. Phenotype of procyclic form APRT null mutants
Double null mutantDtbaprt1,2 procyclics were signiﬁcantly less
sensitive to aminopurinol than their ‘wild-type’ parent (p < 0.001,
one-way Anova followed by Tukey’s multiple comparison test)
even though procyclic cells were already much less sensitive than
bloodstream forms (Fig. 5), conﬁrming that the drug is activated by
phosphoribosyl transfer. This is in agreement with results from L.
donovani, where aminopurinol was used to select for Daprt null
Fig. 7. Inhibition of purine transporters of bloodstream-form T. brucei by aminopurinol. (A) inhibition of the H2 nucleobase transporter using 0.1 lM [3H]-hypoxanthine (de
Koning and Jarvis, 1997), (B) inhibition of the H3 nucleobase transporter using 1 lM [3H]-hypoxanthine (de Koning and Jarvis, 1997), (C) inhibition of the P2 aminopurine
transporter using 0.05 lM [3H]-adenosine in the presence of 1 mM inosine (to saturate P1; Carter and Fairlamb, 1993). All experiments were conducted in triplicate and
standard errors are indicated. Experiments shown are representative of at least three independently conducted experiments. In all cases, incubation time with radiolabel was
30 s, well within the linear phase of uptake (de Koning and Jarvis, 1997, 1999).
Fig. 8. Effect of adenine on aminopurinol sensitivity of wild-type and mutant T.
brucei lines. IC50 values were determined with the Alamar blue assay Räz et al., 1997
in the presence (grey) or absence (white) of 100 lM adenine and are shown on a log
scale. The statistical signiﬁcance (asterisks) was determined on the untransformed
data with two-tailed t-tests. Error bars represent standard deviations of at least
three independent experiments.
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the same mechanism of action as allopurinol, but requires only a
one-step activation by APRT to aminopurinol riboside monophos-
phate. Somewhat surprisingly, given that the purine salvage path-
ways are similar in the two life stages (Fish et al., 1982a,b),
aminopurinol was over two orders of magnitude more active
against bloodstream-form than against procyclic trypanosomes
(Fig. 5). One difference in purine salvage between procyclic and
bloodstream-form trypanosomes is that the aminopurine perme-
ase P2 is only active in the latter (de Koning et al., 1998; de Koning
and Jarvis, 1999), but the relatively low afﬁnity of the compound
for this transporter, and the lack of resistance to aminopurinol in
the Dtbat1 line, show this is not a crucial difference in this case.
Addition of adenine at 100 lM decreased aminopurinol suscepti-
bility in bloodstream-form as well as in procyclic T. brucei
(Fig. 8), as observed previously for T. cruzi (Marr et al., 1978). The
two possible explanations for this observation are that adenine
could either be competing with aminopurinol for transport into
the cell, or alternatively inside the cell at the APRT binding site.
Since 100 lM adenine had no effect on aminopurinol susceptibility
in Dtbaprt1,2 trypanosomes (Fig. 8), the counter-acting effect of
adenine must be caused at the APRT site rather than at the level
of uptake. We conclude that aminopurinol uptake is largely inde-
pendent of any adenine-sensitive transporters and may to a signif-
icant degree involve simple diffusion. Its physical characteristics,which are highly similar to adenine with a XLogP3 of 0.2 (com-
pare 1.1 for hypoxanthine and adenosine (source: pub-
chem.ncbi.nlm.nih.gov)) would allow a sufﬁcient penetration into
the trypanosome considering the duration of the standard drug
sensitivity protocol with Alamar blue (72 h of exposure in vitro).4. Conclusion
T. brucei possess two adenine phosphoribosyltransferase genes
located in tandem on chromosome VII: TbAPRT1 (Tb927.7.1780)
and TbAPRT2 (Tb927.7.1790). The duplication is syntenic in T. con-
golense, T. vivax and T. cruzi, but absent in Leishmania spp. (Fig. 1).
The two genes are expressed in bloodstream-form as well as pro-
cyclic trypanosomes (Fig. 3a). While TbAPRT1 is cytosolic, TbAPRT2
carries a C-terminal PTS1 signal and co-localizes with the glyco-
somal marker aldolase (Figs. 3b and 4). As expected given the high
degree of redundancy of the purine salvage pathways in T. brucei,
TbAPRT1 and TbAPRT2 are not essential genes in vitro and there
was no growth phenotype (Fig. 2a). Double null mutant Dtbaprt1,2
trypanosomes lack APRTase activity (Fig. 2b) which, however, does
not protect them from the toxic effect of high adenine concentra-
tions. Thus, in contrast to the situation in E. coli, adenine toxicity
in T. brucei does not seem to be caused at the level of purine nucle-
otide imbalance and remains an unresolved phenomenon – which
nonetheless demonstrates that trypanosomal purine salvage har-
bors vulnerable targets. The pharmacological importance of purine
salvage was further underscored by the ﬁnding that the Dtbaprt1,2
trypanosomes were resistant to aminopurinol (Fig. 5). With an IC50
of 190 nM (Fig. 5), the adenine isomer aminopurinol is 1000-fold
more active against T. brucei bloodstream forms than the corre-
sponding hypoxanthine isomer allopurinol, consistent with the
model that the aminopurines adenine and adenosine are the pre-
ferred purine sources for bloodstream-form trypanosomes and
analogues thereof the most potent among the trypanocidal purine
antimetabolites. A potential advantage of aminopurinol over aden-
osine analogues is that Dtbat1 trypanosomes are fully sensitive
(Fig. 8). Loss-of-function mutations in TbAT1, the gene encoding
the aminopurine permease P2, have been reported from T. brucei
ﬁeld isolates and implicated in resistance to melaminophenyl
arsenicals, diamidines, and adenosine antimetabolites. Allopurinol
not being suitable against African trypanosomes for lack of efﬁcacy,
aminopurinol may be an interesting alternative for further studies.
However, the ﬁnding that aminopurinol exerts a cytostatic rather
than a cytotoxic effect on bloodstream-form T. brucei (Fig. 6) limits
its potential usefulness.
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